📊 RANI Key Takeaways
Is Rani Therapeutics Holdings, Inc. (RANI) a Good Investment?
Rani Therapeutics is a pre-commercial biotech company with improving fundamentals but unsustainable economics. Revenue grew 58.9% YoY to $1.7M and net losses improved 27.5%, demonstrating progress, yet the company is burning $6.5M annually in cash with severe operating losses (-488% margin). At current burn rate, the $9.6M cash position provides approximately 1.5-2 years of runway before critical capital needs.
Rani Therapeutics Holdings, Inc. Key Strengths (RANI)
- Revenue growing 58.9% YoY demonstrates market traction and commercialization progress
- Net losses improving 27.5% YoY signals path toward profitability
- Strong balance sheet with $9.6M cash, zero long-term debt, and 3.40x current ratio eliminates near-term bankruptcy risk
RANI Stock Risks: Rani Therapeutics Holdings, Inc. Investment Risks
- Severe operating losses at -488% margin with operating income of -$8.3M on only $1.7M revenue indicates unsustainable pre-profitability stage
- Negative operating cash flow of -$6.5M annually creates urgent capital requirements within 18-24 months without significant revenue acceleration
- N/A gross margin and minimal revenue suggest company is pre-major product launch; commercialization success remains unproven
- Early-stage biotech dependency on pipeline progress, regulatory approvals, and market adoption with no visibility into these milestones
Key Metrics to Watch
- Quarterly revenue growth trajectory and path to profitability timeline
- Cash burn rate trends and months of cash runway remaining
- Product launch milestones, regulatory approval status, and commercial traction metrics
Rani Therapeutics Holdings, Inc. (RANI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.40x current ratio provides a solid financial cushion.
RANI Profit Margin, ROE & Profitability Analysis
RANI vs Healthcare Sector: How Rani Therapeutics Holdings, Inc. Compares
How Rani Therapeutics Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rani Therapeutics Holdings, Inc. Stock Overvalued? RANI Valuation Analysis 2026
Based on fundamental analysis, Rani Therapeutics Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rani Therapeutics Holdings, Inc. Balance Sheet: RANI Debt, Cash & Liquidity
RANI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rani Therapeutics Holdings, Inc.'s revenue has declined by 40% over the 5-year period, indicating business contraction. The most recent EPS of $-1.05 indicates the company is currently unprofitable.
RANI Revenue Growth, EPS Growth & YoY Performance
RANI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $172.0K | -$7.0M | $-0.04 |
| Q3 2025 | N/A | -$5.4M | $-0.12 |
| Q2 2025 | N/A | -$6.7M | $-0.18 |
| Q1 2025 | N/A | -$7.3M | $-0.22 |
| Q3 2022 | N/A | -$3.1M | $-0.16 |
| Q2 2022 | N/A | -$7.6M | $0.31 |
| Q1 2022 | $756.0K | -$6.2M | N/A |
| Q3 2021 | N/A | -$2.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rani Therapeutics Holdings, Inc. Dividends, Buybacks & Capital Allocation
RANI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rani Therapeutics Holdings, Inc. (CIK: 0001856725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RANI
What is the AI rating for RANI?
Rani Therapeutics Holdings, Inc. (RANI) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RANI's key strengths?
Claude: Revenue growing 58.9% YoY demonstrates market traction and commercialization progress. Net losses improving 27.5% YoY signals path toward profitability.
What are the risks of investing in RANI?
Claude: Severe operating losses at -488% margin with operating income of -$8.3M on only $1.7M revenue indicates unsustainable pre-profitability stage. Negative operating cash flow of -$6.5M annually creates urgent capital requirements within 18-24 months without significant revenue acceleration.
What is RANI's revenue and growth?
Rani Therapeutics Holdings, Inc. reported revenue of $1.7M.
Does RANI pay dividends?
Rani Therapeutics Holdings, Inc. does not currently pay dividends.
Where can I find RANI SEC filings?
Official SEC filings for Rani Therapeutics Holdings, Inc. (CIK: 0001856725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RANI's EPS?
Rani Therapeutics Holdings, Inc. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RANI's fundamental grade?
Based on our AI fundamental analysis in May 2026, Rani Therapeutics Holdings, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RANI stock overvalued or undervalued?
Valuation metrics for RANI: ROE of -24.8% (sector avg: 15%), net margin of -411.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RANI's AI grade for 2026?
Our dual AI analysis gives Rani Therapeutics Holdings, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RANI's free cash flow?
Rani Therapeutics Holdings, Inc.'s operating cash flow is $-6.5M, with capital expenditures of $15.0K. FCF margin is -381.3%.
How does RANI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -411.8% (avg: 12%), ROE -24.8% (avg: 15%), current ratio 3.40 (avg: 2).